Format

Send to

Choose Destination
Expert Opin Biol Ther. 2017 Mar;17(3):395-402. doi: 10.1080/14712598.2017.1279601. Epub 2017 Jan 25.

Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.

Author information

1
a Department of Dermatology , Venereology & Leprology Postgraduate Institute of Medical Education & Research (PGIMER) , Chandigarh , India.
2
b Dept of Dermatology, Venereology and Leprology , Chitwan Medical College, Tribhuvan University , Bharatpur , Nepal.
3
c Department of Medical affairs , Branded Formulations India , Biocon , Bengaluru , India.

Abstract

Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6. Areas covered: The current article presents the pharmacology of itolizumab and provides a review of the currently available data on the efficacy and safety of itolizumab for management of moderate to severe plaque psoriasis. Expert opinion: The use of biologics to attenuate the immune-mediated pathological events in psoriasis is a relatively well-established clinical practice. However, the safety and efficacy of biologics continues to be an unsettled topic of ongoing research. While available data seems to suggest that itolizumab may be a safer option, additional studies with higher sample sizes and active comparators are needed before definitive conclusions can be drawn on the place of itolizumab in the management of psoriasis.

KEYWORDS:

Anti-CD6; Itolizumab; monoclonal antibody; plaque psoriasis

PMID:
28064543
DOI:
10.1080/14712598.2017.1279601
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center